GlassScriptPhysician profile
Casey Renno
NPI 1144866013
$2,888.05
in general payments reported to CMS, 2019-2025
36 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $588 · 2022: $1,088 · 2023: $602 · 2024: $185 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $476.22 | 2021-2025 | Nplate, Vectibix, Xgeva |
| Novartis Pharmaceuticals Corporation | $233.67 | 2021-2025 | |
| Genzyme Corporation | $194.88 | 2021-2025 | |
| Janssen Biotech, INC. | $167.18 | 2022-2024 | Imbruvica, Darzalex, Rybrevant |
| Lilly USA, LLC | $143.15 | 2021-2025 | Zepbound, Mounjaro, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $133.66 | 2022-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $132.12 | 2022-2025 | Iclusig, Vpriv, Ninlaro |
| Abbvie INC. | $121.62 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $102.44 | 2022-2023 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $100.71 | 2021-2023 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $83.04 | 2023 | Tepmetko, Bavencio |
| Merck Sharp & Dohme LLC | $81.14 | 2021-2022 | |
| Seagen INC. | $71.77 | 2021-2022 | |
| Astellas Pharma US INC | $69.53 | 2021-2025 | Padcev, Veozah |
| Daiichi Sankyo INC. | $68.74 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $68.27 | 2024-2025 | Epkinly |
| G1 Therapeutics, INC. | $67.19 | 2022 | |
| Pfizer INC. | $66.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $64.39 | 2022-2025 | Farxiga |
| Jazz Pharmaceuticals INC. | $61.21 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $49.26 | 2025 | Rexulti |
| Genentech USA, INC. | $44.99 | 2023-2024 | Columvi, Polivy, Lunsumio |
| Morphosys, US INC. | $28.76 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $27.78 | 2024 | |
| Celgene Corporation | $25.23 | 2021-2023 | Reblozyl |
| Beigene USA, INC. | $23.42 | 2023 | Brukinsa |
| Blueprint Medicines Corporation | $23.04 | 2023 | Ayvakit |
| Eisai INC. | $21.68 | 2022 | |
| Beone Medicines USA, INC. | $21.07 | 2025 | Tevimbra |
| Novo Nordisk INC | $19.64 | 2025 | Wegovy |
| Incyte Corporation | $18.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.14 | 2023 | Givlaari |
| Adaptive Biotechnologies Corporation | $15.79 | 2024 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $15.03 | 2022 | |
| Spectrum Pharmaceuticals INC. | $14.63 | 2023 | Rolvedon |
| Axsome Therapeutics, INC. | $14.62 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Renno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.